Drug Profile
Research programme: stem cell modulators - Sumitomo Pharma America
Alternative Names: Cancer stem cell pathway inhibitor - Sumitomo Pharma America; Cancer stemness kinase inhibitor - Sumitomo Pharma America; Stem cell modulating cancer therapeutics - Sumitomo Pharma AmericaLatest Information Update: 21 Jul 2023
Price :
$50
*
At a glance
- Originator Boston Biomedical
- Developer Sumitomo Pharma America
- Class Antineoplastics
- Mechanism of Action Phosphotransferase inhibitors; Signal transduction pathway inhibitors; Stem cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 01 Apr 2022 Sumitomo Dainippon Pharma Oncology is now called Sumitomo Pharma Oncology
- 28 Oct 2020 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 01 Jul 2020 Boston Biomedical has merged with Tolero Pharmaceuticals to form Sumitomo Dainippon Pharma Oncology